<DOC>
	<DOCNO>NCT00721760</DOCNO>
	<brief_summary>The primary objective compare efficacy daily [ q.d ] subcutaneous [ s.c. ] injection Semuloparin sodium ( AVE5026 ) q.d . s.c. injection Enoxaparin prevention Venous Thromboembolic Events [ VTE ] patient undergo hip fracture surgery . The secondary objective evaluate safety AVE5026 patient undergo hip fracture surgery , document AVE5026 exposure population .</brief_summary>
	<brief_title>Evaluation AVE5026 Compared Enoxaparin Prevention Thromboembolism Patients Undergoing Hip Fracture Surgery</brief_title>
	<detailed_description>Randomization take place prior first study drug injection ( randomization ratio 1:1 ) . The total duration observation per participant 35-42 day surgery broken follow : - 7 10-day double-blind treatment period ; - 28 35-day follow-up period . Mandatory bilateral venography lower limb perform 7 11 day surgery .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Standard surgery fracture upper third femur include femoral head neck . Estimated time injury/fracture &gt; 24 hour admission hospital ; Any major orthopedic surgery 3 month prior study start ; Multiple trauma affect one organ system ; Deep vein thrombosis pulmonary embolism within last 12 month know postphlebitic syndrome ; High risk bleeding ; Known allergy heparin , enoxaparin , pork product ; End stage renal disease patient dialysis ; The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hip fracture</keyword>
	<keyword>Heparin Low-Molecular-Weight</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>